Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The preS1 domain is a N-terminal extension of the large HBV surface protein (LHBs), comprising about 108 amino acids (variant depending on genotype). It is myristoylated at its N-terminus, which anchors the domain to the viral envelope. The domain mediates attachment to the hepatocyte-specific receptor, sodium taurocholate cotransporting polypeptide (NTCP), allowing HBV to enter liver cells. It also contains a fusion peptide motif critical for merging the viral envelope with host membranes during infection[2][3][5]. This domain is involved in interactions with the viral capsid for particle assembly, and its structural flexibility (intrinsic disorder) equips it to mediate various functions. Targeting preS1, with drugs or antibodies, is a validated approach to block HBV and hepatitis delta virus (HDV) entry, representing a promising antiviral strategy.[4][5]
Blockade of NTCP binding, preventing viral entry; Inhibition of membrane fusion processes; Neutralization via anti-preS1 antibodies
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PreS1 domain of hepatitis B virus large envelope protein (PreS1 domain).